<DOC>
	<DOCNO>NCT01069471</DOCNO>
	<brief_summary>Healthy volunteer receive 2-dose vaccination Shigella dysenteriae candidate vaccine space 8 week apart . The objective demonstrate safety reactogenicity Shigella dysenteriae bioconjugate vaccine ( GVXN SD133 ) alone combination adjuvant ( Aluminium Hydroxide ) . The safety reactogenicity GVXN SD133 vaccine also evaluate two different concentration antigen , Shigella polysaccharide O1 . Blood sample collect interval examine systemic vaccine antigen-specific immune response .</brief_summary>
	<brief_title>Safety Reactogenicity Bioconjugate Vaccine Prevent Shigella</brief_title>
	<detailed_description />
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Subjects sex , age 18 50 year . Subjects undergone detailed medical history , clinical checkup good health . Subjects understand purpose study freely sign informed consent . Subjects consent repeat blood sample take . Subjects available perform followup visit , reachable telephone , able complete diary card throughout study duration . For female volunteer , negative pregnancy test adequate contraception throughout study duration . Known history recent contact Shigella infection longterm residence Shigella endemic region ( Central America , Africa , India ) . Known history hypersensitivity component vaccine ( EPA ; Aluminium Hydroxide ) . Subjects compromise immune system . Family history congenital hereditary immunodeficiency . Chronic administration immunosuppressive treatment immunemodifying drug within six month prior first vaccine dose . Subjects receive vaccine 1 month precede 1st injection may receive 2nd injection . If subject need vaccinated period , he/she withdrawn study . Subjects suffer disease time enrolment . 'Disease ' define presence mild severe illness without fever . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Any laboratory data collect screen phase find outside normal range define laboratory . Positive test HIV , evidence HBV HCV . Pregnant breastfeed woman . History alcohol , drug psychotropic drug abuse ( interfere normal lifestyle ) previous year . Subjects followup compromise due sociocultural , geographic psychological reason . Any significant finding opinion Investigator would increase risk adverse outcome participate study . Subjects participate participate another clinical trial last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>S.dysenteriae</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Dose scaling</keyword>
</DOC>